Engineered donor cells take on tough leukemia in early trial
Disease control
Recruiting now
This study tests a new treatment called UCART22 for people with a type of blood cancer (B-cell acute lymphoblastic leukemia) that has come back or not responded to standard therapies. UCART22 uses donor immune cells that are engineered to recognize and attack cancer cells carryin…
Phase: PHASE1, PHASE2 • Sponsor: Cellectis S.A. • Aim: Disease control
Last updated May 17, 2026 06:52 UTC